Maravai LifeSciences (MRVI) Social Stream
MARAVAI LIFESCIENCES HOLDINGS INC (MRVI) Price Targets From Analysts
The tables below show price targets and recommendations from analysts covering MARAVAI LIFESCIENCES HOLDINGS INC.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Current Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2021-10-19 | 8 | $62 | $32 | $53.428 | $6.34 | 742.71% |
| 2021-11-11 | 8 | $65 | $49 | $56.166 | $6.34 | 785.9% |
| 2022-01-23 | 6 | $59 | $49 | $54.833 | $6.34 | 764.87% |
| 2022-02-08 | 6 | $59 | $42 | $52.333 | $6.34 | 725.44% |
| 2022-02-24 | 6 | $58 | $42 | $48.5 | $6.34 | 664.98% |
| 2022-05-06 | 6 | $54 | $40 | $46.2 | $6.34 | 628.71% |
| 2022-05-09 | 6 | $49 | $40 | $44.333 | $6.34 | 599.26% |
| 2022-05-20 | 6 | $49 | $40 | $43.833 | $6.34 | 591.37% |
| 2022-07-19 | 7 | $49 | $35 | $42.571 | $6.34 | 571.47% |
| 2022-08-05 | 7 | $40 | $30 | $35.571 | $6.34 | 461.06% |
| 2022-08-13 | 7 | $40 | $30 | $34.428 | $6.34 | 443.03% |
| 2022-10-23 | 7 | $37 | $30 | $34 | $6.34 | 436.28% |
| 2022-11-04 | 8 | $32 | $17 | $24 | $6.34 | 278.55% |
| 2022-12-07 | 8 | $32 | $17 | $23.75 | $6.34 | 274.61% |
| 2023-01-03 | 9 | $32 | $17 | $23.888 | $6.34 | 276.78% |
| 2023-02-08 | 10 | $32 | $16 | $23.1 | $6.34 | 264.35% |
| 2023-02-24 | 10 | $32 | $15 | $21.9 | $6.34 | 245.43% |
| 2023-03-01 | 11 | $32 | $15 | $21.6 | $6.34 | 240.69% |
| 2023-05-09 | 11 | $27 | $15 | $20.3 | $6.34 | 220.19% |
| 2023-08-07 | 11 | $27 | $13 | $19.8 | $6.34 | 212.3% |
| 2023-08-08 | 11 | $27 | $13 | $18.666 | $6.34 | 194.42% |
| 2023-08-09 | 11 | $27 | $11 | $16 | $6.34 | 152.37% |
| 2023-09-19 | 11 | $18 | $8 | $13.555 | $6.34 | 113.8% |
| 2023-11-07 | 11 | $18 | $8 | $13.194 | $6.34 | 108.11% |
| 2023-11-10 | 11 | $18 | $6 | $10.444 | $6.34 | 64.73% |
| 2023-11-13 | 11 | $18 | $6 | $10.333 | $6.34 | 62.98% |
| 2023-12-11 | 11 | $18 | $6 | $10.222 | $6.34 | 61.23% |
| 2023-12-12 | 11 | $18 | $6 | $10.222 | $6.34 | 61.23% |
| 2023-12-29 | 11 | $18 | $6 | $10 | $6.34 | 57.73% |
The Trend in the Analyst Price Target
Over the past 128 days, MRVI's average price target has gone down $3.55.
Over the past 51 weeks, MRVI's average upside potential has been 62.99%.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Share Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2023-08-11 | 11 | 18 | 8 | 13.555 | 10.34 | 31.09% |
| 2023-10-13 | 11 | 18 | 8 | 13.194 | 7.77 | 69.81% |
| 2023-10-31 | 11 | 18 | 8 | 13.194 | 6.86 | 92.33% |
| 2023-12-11 | 11 | 18 | 6 | 10.222 | 5.15 | 98.49% |
| 2023-12-27 | 11 | 18 | 6 | 10.000 | 6.66 | 50.15% |
MRVI Broker Recommendations Summary
| Average Broker Rating | Strong Buy | Buy | Hold | Sell | Strong Sell | Analysts Issuing Recs |
|---|---|---|---|---|---|---|
| 1.68 | 6 | 2 | 3 | 0 | 0 | 11 |
The Trend in the Broker Recommendations
MRVI's average broker recommendation rating worsened by 0.23 over the prior 13 months.
The bullet points below may help you gain a better understanding of what the metrics in the price target and recommendations tables above mean for MRVI as an investment opportunity.
- In terms of how MARAVAI LIFESCIENCES HOLDINGS INC fares relative to all US stocks, note that its upside potential (average analyst target price relative to current price) is greater than 3033.46% of that group.
- In the context of stocks in the large market cap category, MARAVAI LIFESCIENCES HOLDINGS INC's average analyst price target is higher than 608.76% of them.
- In terms of how MARAVAI LIFESCIENCES HOLDINGS INC fares relative to stocks in the large market cap category, note that its number of analysts covering the stock is greater than 658.43% of that group.
- MRVI has a lower variance in analysts' estimates than -1886.74% of stocks in the large market cap category.
Stocks similar to MARAVAI LIFESCIENCES HOLDINGS INC in the Pharmaceutical Products industry regarding analyst recommendations and price targets are ABCL, BLUE, and NTLA.
View All Top Stocks by Price Target
Is MRVI a Buy, Hold or Sell? See the POWR Ratings now!